2023 Survey: Automation Is Ubiquitous for Orphan and Specialty Drug Commercialization
87% of Biopharma Respondents Use AI/ML for Post-Market Activities, But Key Missed Opportunities Remain
As Principal for IPM.ai, Dan leads a team that utilizes machine learning, artificial intelligence and advanced analytics to deliver valuable insights that guide and accelerate the clinical and commercial decisions of life sciences companies. With a focus on specialty markets, Dan’s deep expertise in rare disease and oncology disease states helps biopharma clients better understand and more effectively uncover ideal patients and their health care providers. Prior to joining IPM.ai, Dan led commercial operations and clinical analytics projects for ZS Associates. He holds a Master of Business Administration (MBA) from Vanderbilt University.
87% of Biopharma Respondents Use AI/ML for Post-Market Activities, But Key Missed Opportunities Remain
By: Dan Fisher, Principal, IPM.ai